Funding Opportunity RFA-NS-22-001 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven clinical research applications that are focused on discovering novel diagnostic, prognostic, and/or therapeutic biomarkers for the Lewy Body Dementias (LBD).Biomarker research must be conducted in patients with LBD, must follow Parkinson's Disease Biomarker Program (PDBP) protocols for clinical assessment and biospecimen collection,and must be broadly shareable through the PDBP repositories.

Notice NOT-AI-21-067 from the NIH Guide for Grants and Contracts

Notice NOT-DK-21-024 from the NIH Guide for Grants and Contracts

Notice NOT-DE-21-010 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-304 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support a Brazil-US Regional Prospective Observational Research in Tuberculosis (RePORT) network that will leverage the robust clinical research infrastructure of Brazil to advance our current understanding of the community, host and microbial factors that impact outcomes of tuberculosis (TB) infection and TB disease, especially among persons with HIV (PWH), including drug-resistant TB, to facilitate development of tools to improve treatment outcomes at the individual level and to inform strategies to curtail the TB epidemic at the public health level.

Notice NOT-AG-21-032 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-106 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-169 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-170 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-168 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-21-041 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Human Genome Research Institute (NHGRI), National Institute of Biomedical Imaging and Bioengineering (NIBIB), and All of Us Research Program (All of Us). This program is intended to support Early Stage Investigators and New Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) from diverse backgrounds, including those from groups underrepresented in the health-related sciences.

Notice NOT-NS-21-076 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-078 from the NIH Guide for Grants and Contracts

Notice NOT-TR-21-031 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-104 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-105 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-21-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites a single cooperative agreement application to establish a biorepository of human cardiovascular (CV) tissue and an infrastructure for discovery and mechanistic research to increase our knowledge of the CV complications of type 1 diabetes (T1D). Cardiovascular disease (CVD) is the leading cause of death and morbidity for individuals with T1D, but no T1D-specific therapy exists to prevent or treat this complication of diabetes because of challenges from inadequate preclinical models, decades-long disease progression and poorly defined differences in pathogenesis compared to type 2 diabetes (T2D). The FOA will support a two-phase research plan to encourage the use of human CV tissue to overcome these challenges. The goal of the first phase is to establish a biorepository through 1) the collection and storage of human cadaveric tissues from donors with T1D, T2D, and without diabetes; 2) the performance of quality control and basic histopathologic examination; and 3) the creation of a process for distribution of the biosamples and data to qualified investigators. The goal of the second phase is to serve as the Data Coordinating Center for a consortium that will perform a multimodal analysis to deeply phenotype the anatomical, cellular, and molecular composition of the tissues and make the results available in a public data portal.

Funding Opportunity PAR-21-303 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs. Applicants are required to propose partnerships between at least one U.S. institution and one LMIC institution.

Funding Opportunity RFA-CA-21-052 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) is inviting applications to form the Acquired Resistance to Therapy Network (ARTNet). The ARTNet FOA is a reissuance that builds upon the Drug Resistance and Sensitivity Network (DRSN, RFA-CA-17-009) to focus study on the mechanistic basis of acquired resistance to cancer therapies and disease recurrence. Central to the ARTNets structural organization is team science approaches that iteratively bridge basic, pre-clinical, and translational research along the tumor-microenvironment continuum to inform new strategies that can be better translated to overcome significant challenges in acquired resistance to cancer therapies. This FOA will be published in parallel with a companion FOA titled Coordinating and Data Management Center (CDMC) for Acquired Resistance to Therapy Network (ARTNet; U24 Clinical Trial Not Allowed).

Funding Opportunity RFA-CA-21-053 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications from appropriate multidisciplinary groups to support a Coordinating Center to facilitate overall coordination across the Acquired Resistance to Therapy Network (ARTNet; see U54 awards supported under companion RFA-CA-21-052). The overarching goal of the ARTNet is to bridge basic, pre-clinical, and translational research along the tumor-tumor microenvironment continuum to inform new strategies that can be better translated to overcome significant challenges in acquired resistance to cancer therapies. The Coordinating Center will assemble the appropriate infrastructure to facilitate and implement the administrative, outreach, collaborative, and data management activities of the ARTNet.